Developing therapeutic vaccines against Alzheimer%26apos;s disease

作者：Wisniewski Thomas; Drummond Eleanor

来源：Expert Review of Vaccines, 2016, 15(3): 401-415.

DOI：10.1586/14760584.2016.1121815

• tau
• Amyloid-beta
• immunomodulation
• oligomers
• prion disease
• immunotherapy
• neurodegenerative disease

Alzheimer's disease (AD) is the most common form of dementia worldwide. It is characterized by an imbalance between the production and clearance of amyloid beta (A beta) and tau proteins. In AD these normal proteins accumulate, leading to aggregation and a conformational change forming oligomeric and fibrillary species with a high beta-sheet content. Active and passive immunotherapeutic approaches result in dramatic reduction of A beta pathology in AD animal models. However, there is much more limited evidence in human studies of significant clinical benefits from these strategies and it is becoming apparent that they may only be effective very early in AD. Vaccination targeting only tau pathology has shown benefits in some mouse studies but human studies are limited. Greater therapeutic efficacy for the next generation of vaccine approaches will likely benefit from specifically targeting the most toxic species of A beta and tau, ideally simultaneously.

• 出版日期2016-3-3